Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro

Molecular Cancer

Volumn 5, Issue , 2006, Pages

  De Gottardi, Andrea ^a   Dumonceau, Jean Marc ^a   Bruttin, Fabien ^a   Vonlaufen, Alain ^a   Morard, Isabelle ^a   Spahr, Laurent ^a   Rubbia Brandt, Laura ^b   Frossard, Jean Louis ^a   Dinjens, Winand N M ^c   Rabinovitch, Peter S ^d   Hadengue, Antoine ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^d Department of Pathology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; FARNESOID X RECEPTOR; GUGGULSTERONE; PROTON PUMP INHIBITOR; VITAMIN D RECEPTOR;

ADULT; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CELL COUNT; CELL CULTURE; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGUS BIOPSY; ESOPHAGUS MUCOSA; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PATHOPHYSIOLOGY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BARRETT ESOPHAGUS; BIOPSY; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DNA-BINDING PROTEINS; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS, PEPTIC; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PREGNENEDIONES; RECEPTORS, CALCITRIOL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 33750817378     PISSN: 14764598     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-5-48     Document Type: Article

References (29)

1. Sampliner RE: Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998, 93(7):1028-1032.
2. Axelrad AM, Fleischer DE: Esophageal tumors. In Sleisenger and Fordtran's Gastrointestinal and Liver Disease Edited by: Feldman M, Scharschmidt BF, Sleisenger MH. Philadelphia, W.B. Saunders Company; 1998:540-554.
3. Drewitz DJ, Sampliner RE, Garewal HS: The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997, 92(2):212-215.
4. Nehra D, Howell P, Williams CP, Pye JK, Beynon J: Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999, 44(5):598-602.
5. Vaezi MF, Singh S, Richter JE: Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. Gastroenterology 1995, 108(6):1897-1907.
6. Goldstein SR, Yang GY, Curtis SK, Reuhl KR, Liu BC, Mirvish SS, Newmark HL, Yang CS: Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 1997, 18(11):2265-2270.
7. Nishijima K, Miwa K, Miyashita T, Kinami S, Ninomiya I, Fushida S, Fujimura T, Hattori T: Impact of the biliary diversion procedure on carcinogenesis in Barrett's esophagus surgically induced by duodenoesophageal reflux in rats. Ann Surg 2004, 240(1):57-67.
8. van der Woude CJ, Jansen PL, Tiebosch AT, Beuving A, Homan M, Kleibeuker JH, Moshage H: Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype. Hum Pathol 2002, 33(7):686-692.
9. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B: Identification of a nuclear receptor for bile acids. Science 1999, 284(5418):1362-1365.
10. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ: Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296(5571):1313-1316.
11. Repa JJ, Mangelsdorf DJ: The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 2000, 16:459-481.
12. De Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, Ventre G, Bentzen CL, Niesor EJ, Dufour JF: The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci 2004, 49(6):982-989.
13. Shishodia S, Aggarwal BB: Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem 2004, 279(45):47148-47158.
14. Nagpal S, Na S, Rathnachalam R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005, 26(5):662-687.
15. Zhang H, LeCulyse E, Liu L, Hu M, Matoney L, Zhu W, Yan B: Rat pregnane X receptor: molecular cloning, tissue distribution, and xenobiotic regulation. Arch Biochem Biophys 1999, 368(1):14-22.
16. Huber RM, Murphy K, Miao B, Link JR, Cunningham MR, Rupar MJ, Gunyuzlu PL, Haws TF, Kassam A, Powell F, Hollis GF, Young PR, Mukherjee R, Burn TC: Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 2002, 290(1-2):35-43.
17. Niesor EJ, Flach J, Lopes-Antoni I, Perez A, Bentzen CL: The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des 2001, 7(4):231-259.
18. Katada N, Hinder RA, Smyrk TC, Hirabayashi N, Perdikis G, Lund RJ, Woodward T, Klingler PJ: Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch Surg 1997, 132(7):728-733.
19. Dvorakova K, Payne CM, Ramsey L, Bernstein H, Holubec H, Chavarria M, Bernstein C, Sampliner RE, Riley C, Prasad A, Garewal H: Apoptosis resistance in Barrett's esophagus: ex vivo bioassay of live stressed tissues. Am J Gastroenterol 2005, 100(2):424-431.
20. Morales CP, Souza RF, Spechler SJ: Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002, 360(9345):1587-1589.
21. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD: A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002, 296(5573):1703-1706.
22. Burris TP, Montrose C, Houck KA, Osborne HE, Bocchinfuso WP, Yaden BC, Cheng CC, Zink RW, Barr RJ, Hepler CD, Krishnan V, Bullock HA, Burris LL, Galvin RJ, Bramlett K, Stayrook KR: The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol Pharmacol 2005, 67(3):948-954.
23. Alberts DS, Hallum AV 3rd, Stratton-Custis M, Garcia DJ, Gleason-Guzman M, Salmon SE, Santabarbara P, Niesor EJ, Floret S, Bentzen CL: Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. Clin Cancer Res 2001, 7(5):1246-1250.
24. Bishop-Bailey D, Walsh DT, Warner TD: Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci U S A 2004, 101(10):3668-3673.
25. Pera M, Trastek VF, Carpenter HA, Fernandez PL, Cardesa A, Mohr U, Pairolero PC: Influence of pancreatic and biliary reflux on the development of esophageal carcinoma. Ann Thorac Surg 1993, 55(6):1386-92; discussion 1392-3.
26. Lagergren J, Bergstrom R, Lindgren A, Nyren O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999, 340(11):825-831.
27. Palanca-Wessels MC, Klingelhutz A, Reid BJ, Norwood TH, Opheim KE, Paulson TG, Feng Z, Rabinovitch PS: Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model. Carcinogenesis 2003, 24(7):1183-1190.
28. de Both NJ, Wijnhoven BP, Sleddens HF, Tilanus HW, Dinjens WN: Establishment of cell lines from adenocarcinomas of the esophagus and gastric cardia growing in vivo and in vitro. Virchows Arch 2001, 438(5):451-456.
29. Philpott NJ, Turner AJ, Scopes J, Westby M, Marsh JC, Gordon-Smith EC, Dalgleish AG, Gibson FM: The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 1996, 87(6):2244-2251.